OncoMatch/Clinical Trials/NCT02356653
Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
Is NCT02356653 recruiting? Yes, currently enrolling (Jun 2026). This Early Phase 1 trial studies Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs) for leukemia.
Treatment: Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs) — The goal of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia IRB approved protocols that utilize CliniMACs technology for T depletion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Demographics
Lab requirements
Blood counts
per current institutional SOP
Kidney function
per current institutional SOP
Liver function
per current institutional SOP
Hematologic and Organ Function per current institutional SOP
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Children's Hospital of Philadelphia · Philadelphia, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02356653 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 30 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify